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Allergic diseases are sustained by a T-helper 2 polarization leading to interleukin-4 secretion, IgE-dependent inflammation,
and mast cell and eosinophil activation. HLA-G molecules, both in membrane-bound and in soluble forms, play a central role
in modulation of immune responses. Elevated levels of soluble HLA-G (sHLA-G) molecules are detected in serum of patients
with allergic rhinitis to seasonal and perennial allergens and correlate with allergen-specific IgE levels, clinical severity, drug
consumption, and response to allergen-specific immunotherapy. sHLA-Gmolecules are also found in airway epithelium of patients
with allergic asthma and high levels of sHLA-Gmolecules are detectable in plasma and bronchoalveolar lavage of asthmatic patients
correlating with allergen-specific IgE levels. Finally, HLA-G molecules are expressed by T cells, monocytes-macrophages, and
Langerhans cells infiltrating the dermis of atopic dermatitis patients. Collectively, although at present it is difficult to completely
define the role of HLA-G molecules in allergic diseases, it may be suggested that they are expressed and secreted by immune cells
during the allergic reaction in an attempt to suppress allergic inflammation.
1. Introduction
The human major histocompatibility complex (HLA)
encodes two sets of HLA class I molecules, which have been
termed class Ia (or classical) and class Ib (or nonclassical)
molecules. The class Ia antigens include the gene products
of HLA-A, HLA-B, and HLA-C loci and are characterized by
a broad tissue expression and by a high degree of polymor-
phism [1]. The class Ib antigens include the gene products of
HLA-E, HLA-F, and HLA-G loci and are characterized by a
restricted tissue distribution and by a limited polymorphism
[2]. The encoding genes for classical and nonclassical HLA
class I molecules are located on chromosome 6p21 [3]. Since
its original description in the 1980s in choriocarcinoma cells
and primary cytotrophoblast cells in the placenta [4–6],
considerable evidence supports a central role for HLA-G in
the suppression of immune responses, long-term immune
escape, or tolerance and modulation of inflammation.
Allergic diseases are considered as immunoregulatory
disorders with decreased tolerance towards allergens [7].
In this review, we discuss the current knowledge and the
potential role of HLA-G in allergic diseases.
2. HLA-G Structure
Seven HLA-G isoforms generated by alternative splicing of
the primary HLA-G transcript have been characterized. Four
of them, HLA-G1, HLA-G2, HLA-G3, and HLA-G4, are
bound to the cell surface, while the remaining three,HLA-G5,
HLA-G6, andHLA-G7, are detectable in soluble form (sHLA-
G). The membrane HLA-G1 molecule, which is derived
from the translation of the total HLA-G transcript, and
its soluble counterpart HLA-G5 (sHLA-G) have a structure
identical to that of classical HLA-A, HLA-B, and HLA-C
antigens whereas the other isoforms are smaller lacking one
or two domains [8–11]. Truncated isoforms are generated by
excision of one or two exons encoding globular domains
(G1–G4), while translation of either intron 4 or intron 2
yields sHLA-G5–G7 that lack the transmembrane domain
[12]. Furthermore, sHLA-G1 isoform (shed G1 or sHLA-G1)
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derives from the proteolytic cleavage of themembrane bound
HLA-G1. Both HLA-G1 and HLA-G5 have an extracellular
structure that is similar to other classical HLA class I
molecules: a heavy chain of 3 globular domains that are
linked noncovalently to 𝛽2-microglobulin. By contrast, the
other truncated isoforms have a structure similar to HLA
class II and do not bind 𝛽2-microglobulin. Both HLA-G1
and HLA-G5 can homodimerize either in association with
𝛽2-microglobulin or as free heavy chains. These dimers bind
the LIL-RB1/2 (ILT-2/4) receptors for HLA-G with greater
affinity as compared with monomeric HLA-G [13, 14]. HLA-
G1 and HLA-G5 have been found outside the placenta. HLA-
G generally plays immunosuppressive functions and does so
by several mechanisms [15]. Membrane-bound HLA-G1 and
soluble HLA-G1 and HLA-G5 inhibit uterine and peripheral
NK cell activation, CD8+ T-cell mediated cytolysis, and
CD4+ T-cell alloproliferative responses. Furthermore, HLA-
G may also downregulate alloproliferative responses, induce
immune tolerance by promoting the expansion of CD4+
CD25+ FoxP3+ T regulatory (Treg) lymphocytes, and trigger
the differentiation of CD4+ T-cells in suppressor cells [15].
While originally described as “highly” restricted in its tissue
expression, constitutive expression of HLA-G1 and/or HLA-
G5 has been recognized in a number of tissues includ-
ing thymic medulla, pancreatic islet cells, and peripheral
CD14+ mononuclear cells [16, 17]. Both the promoter and
the 3󸀠 untranslated region (UTR) of HLA-G are highly
polymorphic [5, 6]. Three variations in the 3󸀠UTR, a 14 bp
insertion/deletion [18–23], a single nucleotide polymorphism
(SNP) substituting guanine at +3142 [24, 25], and a SNP
substituting adenine at +3187 [24], can lead to differences
in HLA-G expression [12, 25]. However, some polymorphic
sites in the 3󸀠UTR of HLA-G interfere with mRNA stability,
alternative splicing, and binding of specific microRNAs
(miRs) thereby modulating HLA-G mRNA and/or protein
expression [26]. Indeed, overexpression of these miRs had
also functional activities, since these miRs could directly
downregulate HLA-G mRNA and/or HLA-G surface expres-
sion. Furthermore, cytokines such as interferon- (IFN-) 𝛾
and interleukin- (IL-) 10 trigger the expression of HLA-G by
peripheral blood mononuclear cells (PBMCs) [27, 28]. IL-10
is a key regulator of immune and inflammatory responses and
HLA-G plays an essential role in fetomaternal tolerance by
inhibiting lysis by maternal NK cells. IL-10 enhances steady-
state levels of HLA-G transcription in cultured trophoblast
cells upregulating HLA-G cell surface expression in this cell
type. Moreover, IL-10 is able to enhance HLA-G expression
and to downregulate classicalHLA class I and class II antigens
on monocytes, thus regulating NK cells and T lymphocyte
responses. These characteristics suggest that IL-10 could be
proposed as immunosuppressor agent in the treatment of
transplantation rejection and autoimmune diseases [27, 28].
3. HLA-G and Allergic Rhinitis
Allergic rhinitis (AR) is sustained by mucosal IgE-dependent
inflammation which is promoted, maintained, and amplified
by T-helper (Th) 2 cells [29]. The mucosal inflammation
is characterized by mast cell and eosinophil activation.
Interleukin- (IL-) 4 is a pivotal cytokine that orchestrates
allergic inflammation, because it is the most important
signal to induce Th2 polarization in allergic patients. IL-
4 and IL-13 promote IgE synthesis, upregulate adhesion
molecules selective for eosinophil recruitment, and cause
increased mucous production and airway hyperreactivity
[30–32]. Furthermore, peripheral blood mononuclear cells
of AR patients predominantly produce IL-4 [33]. However, a
defect in Treg lymphocytes has been demonstrated in allergic
patients [7, 34]. Therefore, allergic diseases are considered as
immunoregulatory disorders with reduced tolerance towards
allergens [7]. These pathophysiologic events promote the
production of allergen-specific IgE.
Our group investigated sHLA-A, sHLA-B, sHLA-C, and
sHLA-G serum levels in AR patients allergic to Betula alba,
Parietaria judaica, and Graminaceae [35]. sHLA-A, sHLA-
B, and sHLA-C serum levels were significantly higher in AR
patients as compared to healthy controls (1309 ± 73.3 ng/mL
and 1001 ± 145.7 ng/mL, resp., 𝑝 = 0.011). sHLA-G serum
levels were also significantly higher in AR patients than in
healthy controls (35.86 ± 2.7 ng/mL and 12.79 ± 2.4 ng/mL,
resp., 𝑝 < 0.0001). Moreover, we found a moderate but sig-
nificant correlation between sHLA-G and sHLA-A, sHLA-B,
and sHLA-C levels in AR patients (𝑟 = 0.37). Serum sHLA-G
levelswere also evaluated in patientswithARdue to perennial
allergens including house dust mite and cat and dog dandruff
[36, 37]. Clinical severitywas evaluatedwith a validated visual
analogue scale (VAS) for quantifying the perception of nasal
symptoms intensity and drug consumption at the end of the
pollen season [38]. The serum levels of sHLA-G molecules
resulted as significantly higher in patients with perennial AR
than in healthy controls (𝑝 < 0.0001). Notably, there was a
strong correlation between sHLA-G serum levels, VAS score
(𝑟 = 0.850, 𝑝 < 0.001), and drug use (𝑟 = 0.793, 𝑝 < 0.001).
Notably, a significant even though weak correlation between
serum sHLA-A, sHLA-B, and sHLA-C levels and VAS was
also observed (𝑟 = 0.309, 𝑝 = 0.016) but not between serum
sHLA-A, sHLA-B, and sHLA-C levels and drug consumption
[37]. A further study showed that serum sHLA-G levels were
significantly associated with allergen-specific IgE levels both
in allergic rhinitis (𝑟 = 0.468 and 𝑝 = 0.003) and in allergic
asthma (𝑟 = 0.479 and 𝑝 = 0.006) patients [39]. Finally,
serum sHLA-G levels were higher in patients with seasonal
allergy than in those with perennial allergy (𝑝 = 0.0194)
[40]. Data from another group confirmed that serum sHLA-
G levels are significantly higher also in children with allergic
diseases [41].
AR management includes patient education, allergen
avoidance, drug treatment, and, when appropriate, allergen-
specific immunotherapy [42]. The aim of allergen-specific
sublingual immunotherapy (SLIT) is to achieve clinical tol-
erance to the causal allergen through oral administration
of high-dose allergens by shifting Th2 immune response,
mainly mediated by IL-4, to Th1 response, mainly mediated
by interferon- (IFN-) 𝛾. We evaluated sHLA-G and sHLA-
A, sHLA-B, and sHLA-C serum levels before and 3 months
after the end of SLIT and correlated their values with IFN-
𝛾 production by peripheral blood mononuclear cells [43,
44]. sHLA-G levels decreased from 35.86 ± 2.7 ng/mL to
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11.36 ± 1.6 ng/mL (𝑝 < 0.0001) and sHLA-A, sHLA-B,
and sHLA-C levels decreased from 1309 ± 73.3 ng/mL to
695.3 ± 33.2 ng/mL (𝑝 < 0.0001). Notably, IFN-𝛾 production
increased from 44 ± 68 spots before SLIT to 181 ± 89 spots
after SLIT (𝑝 < 0.0001) and significantly correlated with
both sHLA-G (𝑟 = −0.39, 𝑝 = 0.023) and sHLA-A, sHLA-B,
and sHLA-C (𝑟 = −0.38, 𝑝 = 0.029) changes. Furthermore,
the percentage changes of sHLA-G and sHLA-A, sHLA-
B, and sHLA-C levels were significantly correlated among
themselves (𝑟 = 0.84) and with VAS score (𝑟 = 0.63 and
𝑝 = 0.60, resp.).
4. HLA-G and Asthma
Persistent airway inflammation, structural remodelling, and
bronchial hyperresponsiveness in lower airways are hall-
marks of allergic asthma [45, 46]. Allergen-driven activation
of Th2 CD4+ T-lymphocytes releasing IL-4, IL-5, and IL-
13 perpetuate the inflammation via recruitment of other
lymphocytes, eosinophils, and mononuclear cells [47–49].
Genetic factors play a central role in asthma pathogenesis.
Indeed, over 100 genes have been implicated in asthma
susceptibility [50]. One of such genes may be HLA-G. In
fact, HLA-G genetic polymorphisms confer susceptibility to
airway hyperresponsiveness and asthma development [3].
The G/G genotype at SNP-964 in the promoter region
4 is associated with asthma in the offspring of mothers
with asthma or bronchial hyperresponsiveness (BHR), while
the A/A genotype was associated with asthma in the off-
spring of asthma- and BHR-free mothers [37]. Tan et al.
[51] demonstrated that the SNP-964G/A tagged two major
promoter haplotype clades with evidence of longstanding
balancing selection amongst African Americans, European
Americans, and Han Chinese individuals. There is a strong
linkage disequilibrium between SNPs in the HLA-G gene.
The +3142C/G SNP, which is located in the 3󸀠UTR of the
HLA-G gene, affects the targeting of miR-148a, miR-148b,
and miR-152 and interacts with mother’s asthma status to
determine risk of asthma in the child [24]. Notably, the
+3142 (rs10633320) G/G SNP resulted as protective against
asthma among offspring of asthmatic mothers whereas the
C allele was associated with asthma risk in the offspring of
mothers without asthma. Statins upregulate miR-148b and
miR-152 and, thus, affect HLA-G expression. It has been
found that subjects carrying at least one copy of the G minor
allele of the rs10633320 presented a decreased frequency of
asthma-related exacerbations (emergency department visit,
hospitalizations, or oral corticosteroid use). Moreover, there
was no difference in exacerbation frequency between G/G
and G/C genotypes [52]. A genome-wide association study
(GWAS) confirmed in 6819 participants from the Framing-
ham Heart Study the association of previously described
genetic variants in FCERIA, STAT6, and IL-13 and identified
potential susceptibility loci in the HLA-A, HLA-G, andHLA-
DQA2 gene regions as risk factors for IgE dysregulation
and atopy [53]. KIR2DL4 (CD158d) is a member of the
killer cell immunoglobulin-like receptor family that is mainly
expressed on natural killer (NK) cells and its ligand has
been reported to be HLA-G [54–58]. Furthermore, NK-cell
derived IFN-𝛾 secretion has been reported to be critical
for the generation of tolerogenic dendritic cell (DC) in the
placenta [59]. It might be predicted that individuals with the
functionally defective 9A allele of KIR2DL4would not be able
to secrete IFN-𝛾 and might therefore be prone to producing
Th2-biased immune responses and fewer tolerogenic DC.
KIR2DL4 genotypes were analyzed in 2 cohorts of children
at high risk for atopic disease [60]. However, there was
neither significant relationship between KIR2DL4 genotype
and the prevalence of atopy, as assessed by allergen skin
prick testing in either cohort at any age, nor was there
any significant relationship between KIR2DL4 genotype and
the prevalence of wheeze, bronchial hyperreactivity, and
asthma. A role for HLA-G in asthma pathogenesis was
further suggested by the demonstration of the expression
of the sHLA-G5 isoform in the airway epithelium and of
increased circulating plasma levels of sHLA-G in children
with atopic asthma [61]. Because airway inflammation in
asthma involves a Th-2 skewing of lymphocytes similar
to pregnancy, HLA-G is an attractive candidate molecule
for promoting the immune profile characteristic of asthma.
Localization of HLA-G in airway epithelium suggests that
it could contribute to immune dysregulation and airway
inflammation in chronic asthma. Tahan and Patiroglu [61]
measured sHLA-G levels in bronchoalveolar lavage (BAL)
of patients with mild persistent asthma and found increased
levels as compared to controls (𝑝 = 0.01). Notably, there was
no significant difference in sHLA-G BAL levels in Caucasian
individuals as compared to African-American individuals.
Furthermore, sHLA-G was present in the epithelium of
endobronchial biopsies from 9 of 11 patients with asthma.
These findings supported and confirmed a role for sHLA-G in
asthma pathogenesis. Zheng et al. [62] confirmed that plasma
sHLA-G levels were significantly higher in atopic asthmatic
children than in healthy controls (𝑝 < 0.001). However, no
significant association was observed between plasma sHLA-
G, total IgE, and allergen-specific IgE levels.Moreover, sHLA-
G levels were not significantly related to HLA-G 14 bp
insertion/deletion polymorphism both in asthmatic children
and in controls. On the contrary, we found a significant
association between sHLA-G levels and allergen-specific IgE
levels both in AR (𝑟 = 0.468 and 𝑝 = 0.003) and in
asthmatic (𝑟 = 0.479 and 𝑝 = 0.006) patients [36]. Mapp et
al. [63] demonstrated that baseline levels of IL-10 secretion
by PBMC in patients with isocyanate-induced asthma and
asymptomatic-exposed individuals are higher than those in
nonoccupational allergic asthma and in healthy controls
(𝑝 < 0.0001). Spontaneous production of sHLA-Gby PBMCs
resulted as significantly higher in patients with isocyanate-
induced asthma than in the other groups (𝑝 < 0.005).
5. HLA-G, Allergy and Pregnancy
Rizzo et al. [64] evaluated the potential role of pregnancy
and labor on plasma sHLA-G and IL-10 levels in women
with AR or asthma and in healthy pregnant women. Plasma
samples were obtained during the 3rd trimester of pregnancy,
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at delivery, and at a nonpregnant state 2 years postpartum.
The plasma levels of sHLA-G1 isoform and IL-10 resulted
as significantly increased during labor in comparison with
the levels detected during the 3rd trimester and 2 years after
delivery (𝑝 < 0.0001). However, allergic women had lower
plasma sHLA-G levels than nonallergic women during the
3rd trimester of pregnancy and at delivery (𝑝 < 0.01 and
𝑝 < 0.05, resp.). Interestingly, no significant differences were
found in samples obtained 2 years after pregnancy. Thymus-
and-activation-regulated chemokine (TARCorCCL17) is one
of the Th2-inducible chemokines produced by the thymus
[65] and by trophoblasts and endometrial gland cells dur-
ing pregnancy [65]. CCL17 is related to both allergy and
pregnancy. Miyahara et al. [66] enrolled 70 paired full-term
and normal-vaginal-delivery newborns and their mothers
and reported that serum levels of CCL17 were higher in
mothers with atopic dermatitis (AD) than in those without
AD (𝑝 < 0.001). High umbilical cord serum levels of CCL17
were associated with infantile AD development (𝑝 < 0.001).
Serum levels of CCL17 (𝑟s = 0.340, 𝑝 < 0.001) and sHLA-
G (𝑟s = 0.600, 𝑝 < 0.001) showed high correlations between
umbilical cord and maternal blood.
6. HLA-G and Atopic Dermatitis
Atopic dermatitis (AD) is a chronic disease usually beginning
in childhood. AD is characterized by increased production
of IL-4, IL-13, and IgE [67]. In AD biopsies, HLA-G positive
cells were always found in the papillary and, less frequently,
in the reticular dermis [64]. HLA-G was expressed mainly
by infiltrating T cells but also, to a lesser extent and less
frequently, by monocytes-macrophages or Langerhans cells
[68].
7. What Is the Role of HLA-G in the
Pathogenesis of Allergic Diseases?
HLA-G molecules have a complex immune regulatory role
in transplantation, cancer, viral infections, chronic inflam-
matory diseases, and pregnancy [8, 9, 69–72]. In general,
HLA-G is a tolerance-inducing molecule but it is also a
stimulus for Th2 responses and Treg cells activation [73].
Allergic diseases are driven by aTh2-polarized inflammation
[74] and allergic patients display a defect in Treg cells which
may be restored by specific immunotherapy [34]. At present,
it is difficult to completely clarify the role of HLA-G in
allergic diseases. It may be suggested that they are expressed
and secreted by immune cells during the allergic reaction
and may represent a reactive attempt to suppress allergic
inflammation. This hypothesis is supported by their increase
during immunotherapy and is in keeping with the finding
that antigen presenting cells andmonocytes expressingHLA-
G molecules are able to create a tolerogenic milieu enriched
in IL-10 which, in turn, promotes Treg cells activity [75,
76]. HLA-G genetic polymorphisms confer susceptibility
to airway hyperresponsiveness and asthma development.
In particular, G/G genotype at SNP-964G/A in the pro-
moter region is associated with asthma; the +3142C/G SNP
increases the risk of asthma in the child. By contrast, the
+3142 (rs10633320) G/G SNP resulted as protective against
asthma development. In conclusion, it could be postulated
that increased HLA-G levels could be either compensatory
or pathogenetic through mechanisms not yet completely
known. Accordingly, it has been recently proposed that HLA-
G should be no longer qualified as a “shield” to protect
tissues and cells from immune destruction but, rather, as an
“immune checkpoint” molecule [77].
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